½ÃÀ庸°í¼­
»óǰÄÚµå
1602231

°üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå : Á¦Ç°, °ø±Þ¿ø, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Viscosupplementation Market by Product (Five Injection, Single Injection, Three Injection), Source (Animal, Non-animal), Application, End-use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 197 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀåÀº 2023³â¿¡ 28¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 30¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.19%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 43¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°üÀý³» ġȯ¼úÀº °üÀý¿¡ È÷¾Ë·ç·Ð»êÀ» ÁÖÀÔÇÏ¿© ÅëÁõÀ» ¿ÏÈ­Çϰí ÁÖ·Î °ñ°üÀý¿° ȯÀÚÀÇ À̵¿¼ºÀ» Çâ»ó½ÃŰ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. °üÀý³» ġȯ¼úÀÇ Çʿ伺Àº ±âÁ¸ Ä¡·á¹ýÀÌ ºÒÃæºÐÇÑ °æ¿ì Å« ¿ÏÈ­¸¦ °¡Á®¿Ã ¼ö ÀÖÀ¸¹Ç·Î ¼ö¼úÀû ¼±Åÿ¡ ¾Õ¼­ Áß°£ ÇØ°áÃ¥À¸·Î ÀÛ¿ëÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÁÖ·Î Á¤Çü¿Ü°úÀû Ä¡·á, ƯÈ÷ ¹«¸­ °ñ°üÀý¿°¿¡ ÁÖ·Î »ç¿ëµÇÁö¸¸, °í°üÀý, ¹ß¸ñ, ¾î±ú °üÀý¿¡µµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â º´¿ø ¹× Ŭ¸®´Ð¿¡¼­ ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, ÀÌ´Â ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ÀÇ ÀûÀÀ¼ºÀ» ¹Ý¿µÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¼¼°è Àα¸ÀÇ °í·ÉÈ­, °ñ°üÀý¿°ÀÇ À¯º´·ü Áõ°¡, ºñ¼ö¼úÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ÀÔ´Ï´Ù. È÷¾Ë·ç·Ð»ê Á¦Á¦ÀÇ ±â¼úÀû ¹ßÀü°ú ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú °°Àº ¹Ì°³Ã´ ½ÅÈï ½ÃÀå¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ¸é¼­ ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´õ ¿À·¡ Áö¼ÓµÇ´Â Á¦Çü°ú ´õ ³ªÀº È¿´ÉÀ» Á¦°øÇÏ´Â Àü´Þ ¹æ¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ±âȸ°¡ ÀÖ½À´Ï´Ù. ±×·¯³ª °üÀý³» ġȯ¼ú¿¡ ´ëÇÑ ºñ¿ë°ú Àϰü¼º ¾ø´Â »óȯ Á¤Ã¥, ȯÀÚ ¹ÝÀÀÀÇ ÆíÂ÷, ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵峪 Ç÷¼ÒÆÇdzºÎÇ÷Àå ¿ä¹ý°ú °°Àº ´ëü Ä¡·á¹ý°úÀÇ °æÀï µî Á¦¾àÀÌ ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å°ú ¿¬±¸´Â ¼­¹æÇü È÷¾Ë·ç·Ð»ê Á¦Ç°°ú Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇØ Ç׿°Áõ¾à¿ÍÀÇ º´¿ë ¿ä¹ý°ú °°Àº »õ·Î¿î Àü´Þ Ç÷§Æû¿¡ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. ½ÃÀåÀº Ä¡¿­ÇÑ °æÀï°ú ºü¸¥ ¹ßÀüÀÌ Æ¯Â¡ÀÎ ¸¸Å­ ¾÷°è ±â¾÷Àº ²÷ÀÓ¾øÀÌ Çõ½ÅÇÏ°í º¯È­ÇÏ´Â ±ÔÁ¦ ½Ã³ª¸®¿À¿Í °í°´ÀÇ ±â´ë¿¡ ÀûÀÀÇØ¾ß ÇÕ´Ï´Ù. ±â¾÷Àº µðÁöÅРä³ÎÀ» Ȱ¿ëÇÏ¿© ÀÇ·á Àü¹®°¡¿Í ȯÀÚ¿¡°Ô Ä¡·áÀÇ ÀÌÁ¡À» ¾Ë¸®°í º¸±ÞÀ» ÃËÁøÇϱâ À§ÇØ µðÁöÅРä³ÎÀ» Ȱ¿ëÇØ¾ß ÇÕ´Ï´Ù. ȯÀÚ Áß½ÉÀÇ ¿¬±¸¸¦ ¿ì¼±½ÃÇϰí ÀÓ»ó ÀûÀÀÁõÀ» È®´ëÇÏ´Â °ÍÀÌ ÇâÈÄ ½ÃÀå ¼º°øÀ» À§ÇØ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 28¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 30¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 43¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 6.19%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â °üÀý³» ġȯ¼ú ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Àΰø°üÀý ġȯ¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °ñ°üÀý¿°ÀÇ ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
    • ½Ä½À°ü º¯È­¿¡ µû¸¥ »ýȰ½À°üº´ Áõ°¡
    • Àü ¼¼°è ³ëÀÎ Àα¸¿Í ºñ¸¸ ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • È÷¾Ë·ç·Ð»ê ±â¹Ý Ä¡·á·Î ÀÎÇÑ ºÎÀÛ¿ë ¹× ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • È÷¾Ë·ç·Ð»ê ±â¹Ý Ä¡·á¹ý °³¹ßÀÇ Áö¼ÓÀûÀÎ ¹ßÀü
    • ½½°³°ñ ¿¬°ñÁõ¿¡ ´ëÇÑ °üÀý³» ġȯ¼úÀÇ ¿ªÇÒ È®´ë
  • ½ÃÀå °úÁ¦
    • ¾ö°ÝÇÑ ½ÂÀÎ ±ÔÁ¤°ú ªÀº À±È° ¹× ÁøÅë È¿°ú Áö¼Ó ½Ã°£

Porter's Five Forces: °üÀý³» ġȯ¼ú ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °üÀý³»Àåºñ·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Àΰø°üÀý ġȯ¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °üÀý³» ġȯ¼ú ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

°üÀý³» ġȯ¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º °üÀý³» ġȯ¼ú ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °üÀý³» ġȯ¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå : Á¦Ç°º°

  • 5ȸ ÁÖ»ç
  • 1ȸ ÁÖ»ç
  • 3ȸ ÁÖ»ç

Á¦7Àå °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå : ¼Ò½ºº°

  • µ¿¹°
  • ºñµ¿¹°

Á¦8Àå °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå : ¿ëµµº°

  • ¼Õ °ñ°üÀý¿°
  • º¯Çü¼º °í°üÀýÁõ
  • º¯Çü¼º ½½°üÀýÁõ

Á¦9Àå °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • Á¤Çü¿Ü°ú Ŭ¸®´Ð/¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °üÀý³» º¸Ãæ ¿ä¹ý ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Avanos Medical, Inc.
  • Viatris Inc.
  • LG Chem Ltd.
  • Anika Therapeutics, Inc.
  • Quimfa S.A.
  • Sanofi S.A.
  • Contipro A.S.
  • Lifecore Biomedical, LLC
  • Smith & Nephew PLC
  • Bioventus LLC
  • Fidia Farmaceutici S.p.A.
  • Alcon Inc.
  • Seikagaku Corporation
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • Zimmer Biomet
  • Regen Lab SA
  • Gentex Pharma, LLC
  • Bausch Health Companies Inc.
  • AbbVie Inc.
  • DePuy Synthes by Johnson & Johnson Services, Inc.
KSA 24.12.10

The Viscosupplementation Market was valued at USD 2.83 billion in 2023, expected to reach USD 3.01 billion in 2024, and is projected to grow at a CAGR of 6.19%, to USD 4.32 billion by 2030.

Viscosupplementation is a medical procedure involving the injection of hyaluronic acid into joints to alleviate pain and improve mobility, primarily for those with osteoarthritis. The necessity of viscosupplementation arises due to its potential to provide significant relief where conventional therapies may not suffice, acting as an intermediate solution before surgical options. Its application is mainly in orthopedic care, particularly for knee osteoarthritis, although research is expanding its use to hip, ankle, and shoulder joints as well. End-use spans from hospitals and clinics to ambulatory surgical centers, reflecting its adaptability in various healthcare settings. Market growth is chiefly driven by the aging global population, the rising prevalence of osteoarthritis, and increasing awareness of non-surgical treatment alternatives. Technological advancements in hyaluronic acid formulations and the growing focus on minimally invasive procedures further stimulate demand. Opportunities lie in untapped emerging markets like Asia-Pacific, where improving healthcare infrastructure is fostering market entry. There is a cross-sectional opportunity in developing enhanced, longer-lasting formulations and delivery methods that could provide superior efficacy. However, limitations include the cost of viscosupplementation and inconsistent reimbursement policies, while challenges include variability in patient response and competition from alternative treatments like corticosteroids and platelet-rich plasma therapies. Innovation and research should focus on novel delivery platforms, such as sustained-release hyaluronic acid products or combination therapies that incorporate anti-inflammatory agents to enhance treatment outcomes. The market is characterized by strong competition and rapid advancements, thus industry players must continuously innovate and adapt to shifting regulatory scenarios and customer expectations. Companies should leverage digital channels to educate healthcare professionals and patients on treatment benefits to drive adoption. Prioritizing patient-centric research and expanding clinical indications will be crucial for future market success.

KEY MARKET STATISTICS
Base Year [2023] USD 2.83 billion
Estimated Year [2024] USD 3.01 billion
Forecast Year [2030] USD 4.32 billion
CAGR (%) 6.19%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viscosupplementation Market

The Viscosupplementation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Need for Non-Surgical Treatment for Osteoarthritis
    • Rising Occurrence of Lifestyle-Induced Disorders with Changing Eating Habits
    • Surge in Geriatric Population and Obesity Globally
  • Market Restraints
    • Side Effects and High Cost of The Hyaluronic Acid-Based Treatment
  • Market Opportunities
    • Ongoing Advancements in the Development of Hyaluronic Acid-Based Therapies
    • Extending Role of Viscosupplementation in Patellar Chondropathy
  • Market Challenges
    • Strict Regulatory Mandates for Approval and Short Duration of Lubrication and Pain Relief

Porter's Five Forces: A Strategic Tool for Navigating the Viscosupplementation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viscosupplementation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viscosupplementation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viscosupplementation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viscosupplementation Market

A detailed market share analysis in the Viscosupplementation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viscosupplementation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viscosupplementation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Viscosupplementation Market, highlighting leading vendors and their innovative profiles. These include Avanos Medical, Inc., Viatris Inc., LG Chem Ltd., Anika Therapeutics, Inc., Quimfa S.A., Sanofi S.A., Contipro A.S., Lifecore Biomedical, LLC, Smith & Nephew PLC, Bioventus LLC, Fidia Farmaceutici S.p.A., Alcon Inc., Seikagaku Corporation, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Ferring B.V., Zimmer Biomet, Regen Lab SA, Gentex Pharma, LLC, Bausch Health Companies Inc., AbbVie Inc., and DePuy Synthes by Johnson & Johnson Services, Inc..

Market Segmentation & Coverage

This research report categorizes the Viscosupplementation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Five Injection, Single Injection, and Three Injection.
  • Based on Source, market is studied across Animal and Non-animal.
  • Based on Application, market is studied across Hand Osteoarthritis, Hip Osteoarthritis, and Knee Osteoarthritis.
  • Based on End-use, market is studied across Hospitals and Orthopedic Clinics/Ambulatory Surgical Centers (ASCs).
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Need for Non-Surgical Treatment for Osteoarthritis
      • 5.1.1.2. Rising Occurrence of Lifestyle-Induced Disorders with Changing Eating Habits
      • 5.1.1.3. Surge in Geriatric Population and Obesity Globally
    • 5.1.2. Restraints
      • 5.1.2.1. Side Effects and High Cost of The Hyaluronic Acid-Based Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Advancements in the Development of Hyaluronic Acid-Based Therapies
      • 5.1.3.2. Extending Role of Viscosupplementation in Patellar Chondropathy
    • 5.1.4. Challenges
      • 5.1.4.1. Strict Regulatory Mandates for Approval and Short Duration of Lubrication and Pain Relief
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Products: Burgeoning adoption of a three-injection regimen to reduce pain and enhance mobility in patients with osteoarthritis
    • 5.2.2. Source: Growing preference for non-animal-based hyaluronic acid as it eliminates hypersensitivity reaction risks
    • 5.2.3. Applications: Evolving applications of viscosupplementation treatment for knee osteoarthritis
    • 5.2.4. End-use: Proliferating utilization of viscosupplementation treatment in orthopedic clinics/ambulatory surgical centers (ASCs)
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Viscosupplementation Market, by Product

  • 6.1. Introduction
  • 6.2. Five Injection
  • 6.3. Single Injection
  • 6.4. Three Injection

7. Viscosupplementation Market, by Source

  • 7.1. Introduction
  • 7.2. Animal
  • 7.3. Non-animal

8. Viscosupplementation Market, by Application

  • 8.1. Introduction
  • 8.2. Hand Osteoarthritis
  • 8.3. Hip Osteoarthritis
  • 8.4. Knee Osteoarthritis

9. Viscosupplementation Market, by End-use

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)

10. Americas Viscosupplementation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Viscosupplementation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Viscosupplementation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. KiOmed Pharma and Arsylab Announce Strategic Partnership for the Promotion and Distribution in France of KioMedinevsone, a New Class of Treatment for Refractory Knee Osteoarthritis
    • 13.3.2. Anika's Cingal Successfully Achieves Primary Endpoint in Third Phase III Study

Companies Mentioned

  • 1. Avanos Medical, Inc.
  • 2. Viatris Inc.
  • 3. LG Chem Ltd.
  • 4. Anika Therapeutics, Inc.
  • 5. Quimfa S.A.
  • 6. Sanofi S.A.
  • 7. Contipro A.S.
  • 8. Lifecore Biomedical, LLC
  • 9. Smith & Nephew PLC
  • 10. Bioventus LLC
  • 11. Fidia Farmaceutici S.p.A.
  • 12. Alcon Inc.
  • 13. Seikagaku Corporation
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Ferring B.V.
  • 17. Zimmer Biomet
  • 18. Regen Lab SA
  • 19. Gentex Pharma, LLC
  • 20. Bausch Health Companies Inc.
  • 21. AbbVie Inc.
  • 22. DePuy Synthes by Johnson & Johnson Services, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦